S&P 500   4,274.34 (+0.01%)
DOW   33,513.37 (-0.15%)
QQQ   354.49 (-0.12%)
AAPL   178.51 (-0.60%)
MSFT   333.14 (-0.83%)
META   274.62 (+1.19%)
GOOGL   127.62 (+1.28%)
AMZN   126.88 (+1.26%)
TSLA   219.37 (+0.81%)
NVDA   385.25 (-1.65%)
NIO   7.74 (+0.91%)
BABA   86.63 (+2.64%)
AMD   122.62 (+3.98%)
T   15.73 (+2.21%)
F   12.92 (+2.62%)
MU   68.30 (+0.78%)
CGC   0.75 (-3.63%)
GE   104.99 (+0.85%)
DIS   92.15 (+1.26%)
AMC   4.68 (+1.08%)
PFE   38.63 (-0.05%)
PYPL   64.75 (+0.37%)
NFLX   398.27 (-1.31%)
S&P 500   4,274.34 (+0.01%)
DOW   33,513.37 (-0.15%)
QQQ   354.49 (-0.12%)
AAPL   178.51 (-0.60%)
MSFT   333.14 (-0.83%)
META   274.62 (+1.19%)
GOOGL   127.62 (+1.28%)
AMZN   126.88 (+1.26%)
TSLA   219.37 (+0.81%)
NVDA   385.25 (-1.65%)
NIO   7.74 (+0.91%)
BABA   86.63 (+2.64%)
AMD   122.62 (+3.98%)
T   15.73 (+2.21%)
F   12.92 (+2.62%)
MU   68.30 (+0.78%)
CGC   0.75 (-3.63%)
GE   104.99 (+0.85%)
DIS   92.15 (+1.26%)
AMC   4.68 (+1.08%)
PFE   38.63 (-0.05%)
PYPL   64.75 (+0.37%)
NFLX   398.27 (-1.31%)
S&P 500   4,274.34 (+0.01%)
DOW   33,513.37 (-0.15%)
QQQ   354.49 (-0.12%)
AAPL   178.51 (-0.60%)
MSFT   333.14 (-0.83%)
META   274.62 (+1.19%)
GOOGL   127.62 (+1.28%)
AMZN   126.88 (+1.26%)
TSLA   219.37 (+0.81%)
NVDA   385.25 (-1.65%)
NIO   7.74 (+0.91%)
BABA   86.63 (+2.64%)
AMD   122.62 (+3.98%)
T   15.73 (+2.21%)
F   12.92 (+2.62%)
MU   68.30 (+0.78%)
CGC   0.75 (-3.63%)
GE   104.99 (+0.85%)
DIS   92.15 (+1.26%)
AMC   4.68 (+1.08%)
PFE   38.63 (-0.05%)
PYPL   64.75 (+0.37%)
NFLX   398.27 (-1.31%)
S&P 500   4,274.34 (+0.01%)
DOW   33,513.37 (-0.15%)
QQQ   354.49 (-0.12%)
AAPL   178.51 (-0.60%)
MSFT   333.14 (-0.83%)
META   274.62 (+1.19%)
GOOGL   127.62 (+1.28%)
AMZN   126.88 (+1.26%)
TSLA   219.37 (+0.81%)
NVDA   385.25 (-1.65%)
NIO   7.74 (+0.91%)
BABA   86.63 (+2.64%)
AMD   122.62 (+3.98%)
T   15.73 (+2.21%)
F   12.92 (+2.62%)
MU   68.30 (+0.78%)
CGC   0.75 (-3.63%)
GE   104.99 (+0.85%)
DIS   92.15 (+1.26%)
AMC   4.68 (+1.08%)
PFE   38.63 (-0.05%)
PYPL   64.75 (+0.37%)
NFLX   398.27 (-1.31%)
NASDAQ:FATE

Fate Therapeutics (FATE) Stock Forecast, Price & News

$5.36
+0.20 (+3.88%)
(As of 12:39 PM ET)
Compare
Today's Range
$5.06
$5.42
50-Day Range
$4.89
$6.59
52-Week Range
$4.02
$37.13
Volume
837,275 shs
Average Volume
3.19 million shs
Market Capitalization
$527.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.50

Fate Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.14 Rating Score
Upside/​Downside
189.2% Upside
$15.50 Price Target
Short Interest
Bearish
31.55% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.70
Upright™ Environmental Score
News Sentiment
0.24mentions of Fate Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
Acquiring Shares
$274,000 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.92) to ($2.08) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.74 out of 5 stars

Medical Sector

729th out of 984 stocks

Biological Products, Except Diagnostic Industry

113th out of 159 stocks


FATE stock logo

About Fate Therapeutics (NASDAQ:FATE) Stock

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Receive FATE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FATE Stock News Headlines

How to Invest in AI's Fast-Growing Market
The AI market stands at $160 billion in 2023. Estimates are the AI market will grow 20-fold to $1.8 TRILLION by 2030. One little-known company is looking to win big with a new network technology no one else has. AI could explode... and soon.
Fate Therapeutics (NASDAQ:FATE) Trading Up 6.7%
Soaring EV Industry Keeps Investor Focus on Lithium
The need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.
H.C. Wainwright Remains a Hold on Fate Therapeutics (FATE)
Q1 2023 Fate Therapeutics Inc Earnings Call
Fate Therapeutics (FATE) Gets a Buy from Mizuho Securities
See More Headlines

FATE Price History

FATE Company Calendar

Last Earnings
5/03/2023
Today
6/06/2023
Next Earnings (Estimated)
8/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FATE
Fax
N/A
Employees
449
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.50
High Stock Price Forecast
$65.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+200.4%
Consensus Rating
Hold
Rating Score (0-4)
2.14
Research Coverage
21 Analysts

Profitability

Net Income
$-281,720,000.00
Net Margins
-171.64%
Pretax Margin
-171.64%

Debt

Sales & Book Value

Annual Sales
$96.30 million
Book Value
$4.98 per share

Miscellaneous

Free Float
93,425,000
Market Cap
$507.64 million
Optionable
Optionable
Beta
1.49

Key Executives

  • J. Scott WolchkoJ. Scott Wolchko
    President, Chief Executive Officer & Director
  • Edward J. DulacEdward J. Dulac
    Chief Financial Officer & Accounting Officer
  • Bahram ValamehrBahram Valamehr
    Chief Research & Development Officer
  • Wen Bo Wang
    Senior Vice President-Technical Operations
  • Yu Waye ChuYu Waye Chu
    Chief Medical Officer













FATE Stock - Frequently Asked Questions

Should I buy or sell Fate Therapeutics stock right now?

21 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last twelve months. There are currently 2 sell ratings, 14 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" FATE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FATE, but not buy additional shares or sell existing shares.
View FATE analyst ratings
or view top-rated stocks.

What is Fate Therapeutics' stock price forecast for 2023?

21 brokers have issued 1 year price targets for Fate Therapeutics' shares. Their FATE share price forecasts range from $5.00 to $65.00. On average, they expect the company's share price to reach $15.50 in the next twelve months. This suggests a possible upside of 200.4% from the stock's current price.
View analysts price targets for FATE
or view top-rated stocks among Wall Street analysts.

How have FATE shares performed in 2023?

Fate Therapeutics' stock was trading at $10.09 at the beginning of 2023. Since then, FATE shares have decreased by 48.9% and is now trading at $5.16.
View the best growth stocks for 2023 here
.

When is Fate Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our FATE earnings forecast
.

How were Fate Therapeutics' earnings last quarter?

Fate Therapeutics, Inc. (NASDAQ:FATE) released its earnings results on Wednesday, May, 3rd. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.36. The biopharmaceutical company had revenue of $58.98 million for the quarter, compared to the consensus estimate of $33.53 million. Fate Therapeutics had a negative net margin of 171.64% and a negative trailing twelve-month return on equity of 45.62%. The firm's revenue was up 220.5% on a year-over-year basis. During the same quarter last year, the firm posted ($0.68) earnings per share.

What is Scott Wolchko's approval rating as Fate Therapeutics' CEO?

2 employees have rated Fate Therapeutics Chief Executive Officer Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among the company's employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Fate Therapeutics own?
What is Fate Therapeutics' stock symbol?

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Who are Fate Therapeutics' major shareholders?

Fate Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include State Street Corp (15.07%), BlackRock Inc. (11.66%), Bank of America Corp DE (2.19%), Two Sigma Advisers LP (1.90%), Two Sigma Investments LP (1.83%) and JPMorgan Chase & Co. (1.75%). Insiders that own company stock include Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, Edward J Dulac III, J Scott Wolchko, John Mendlein, Louis T Petrillo, Mark Plavsic, Redmile Group, Llc, Shefali Agarwal and Yu-Waye Chu.
View institutional ownership trends
.

How do I buy shares of Fate Therapeutics?

Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fate Therapeutics' stock price today?

One share of FATE stock can currently be purchased for approximately $5.16.

How much money does Fate Therapeutics make?

Fate Therapeutics (NASDAQ:FATE) has a market capitalization of $507.64 million and generates $96.30 million in revenue each year. The biopharmaceutical company earns $-281,720,000.00 in net income (profit) each year or ($2.42) on an earnings per share basis.

How many employees does Fate Therapeutics have?

The company employs 449 workers across the globe.

How can I contact Fate Therapeutics?

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.fatetherapeutics.com. The biopharmaceutical company can be reached via phone at (858) 875-1800 or via email at christina@sternir.com.

This page (NASDAQ:FATE) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -